Core Viewpoint - The company Enkang Biotechnology, a subsidiary of Beijiajie, has received FDA-GRAS certification for its probiotic strain BC01, marking it as the first Chinese company to achieve this certification with the specific strain [1][2]. Company Overview - Beijiajie primarily engages in the research, production, and sales of oral hygiene products, disposable sanitary products, and probiotic products, including probiotic raw materials and consumer goods [2]. - Enkang has established two research centers in Suzhou and XuZhou, employing over 40 professionals with master's and doctoral degrees, and has developed a proprietary strain library containing over 12,000 strains [3]. Product Details - The BC01 strain has been authorized with 8 domestic and international patents and has undergone 4 human clinical studies, targeting health issues such as constipation, immune enhancement, and metabolic regulation [2][3]. - The probiotic BC01 can be utilized in various functional food products, beverages, gummies, and snacks, aligning with the growing demand in the health food market [2]. Financial Performance - In the first half of 2025, Beijiajie reported a revenue of 717 million yuan, a year-on-year increase of 15.64%, and a net profit attributable to shareholders of 43.52 million yuan, reflecting a growth of 31.31% [2]. Market Implications - The FDA-GRAS certification signifies that the quality and safety of the BC01 strain meet international standards, allowing for potential exports to the U.S. and other markets recognizing the GRAS certification, which is expected to positively impact Enkang's performance [3].

Core Viewpoint - The company Enkang Biotechnology, a subsidiary of Beijiajie, has received FDA-GRAS certification for its probiotic strain BC01, marking it as the first Chinese company to achieve this certification with the Weizmannia coagulans strain, which is considered a significant milestone in food safety standards [1][2]. Company Overview - Beijiajie primarily engages in the research, development, production, and sales of oral hygiene products, disposable sanitary products, and probiotic products, including probiotic raw materials and consumer products [2]. - Enkang has established two research centers in Suzhou and XuZhou, employing over 40 professionals with master's and doctoral degrees, and has developed a proprietary strain library with over 12,000 strains [3]. Product and Market Potential - The BC01 strain has been authorized with 8 domestic and international patents and has undergone 4 human clinical studies, targeting health issues such as constipation, immune enhancement, micro-ecological regulation, lipid metabolism improvement, and anti-aging [2][3]. - The probiotic can be utilized in various functional food products, beverages, gummies, and snacks, aligning with the growing demand in the health food market [2]. Financial Performance - In the first half of 2025, Beijiajie reported a revenue of 717 million yuan, a year-on-year increase of 15.64%, and a net profit attributable to shareholders of 43.52 million yuan, reflecting a growth of 31.31% [2].

Core Viewpoint - The company Beijiajie (603059.SH) announced that its subsidiary, Shanenkang Biotechnology (Suzhou) Co., Ltd., has received FDA-GRAS certification for its probiotic strain, Weissella confusa BC01, marking a significant compliance and quality achievement that meets international standards [1] Company Summary - Shanenkang becomes the first company in China to obtain FDA-GRAS certification for Weissella confusa [1] - The probiotic strain has been authorized with 8 domestic and international invention patents and has published 2 SCI papers [1] - The company has conducted 4 human clinical studies on the probiotic strain, indicating its potential for diverse applications in functional foods, beverages, gummies, and snacks [1] - The FDA-GRAS recognition is expected to have a positive impact on Shanenkang's performance [1]